Abstract
A lot of different antibodies like anti-myelin basic protein (anti-MBP), anti-S 100, anti-phospholipoprotein (anti-PLP) and anti-myelin oligodendrocyte glycoprotein (anti-MOG) combined with different lymphocyte types and additional factors, e.g., complement are considered as parts of the ethiopathology of multiple sclerosis (MS). In 1990 we published results of a three-armed randomized clinical trial – prednisolone (P) against plasma exchange (PE) plus P against immunoadsorption (IA) (ImmusorbaPH350, Asahi Medical Co., Tokyo, Japan) plus P. 17 MS patients with chronic progression or acute exacerbation were included; PE and IA were superior to P alone in short-time follow-up. A reduction of complement activation of 75% by waste in PE or by removal in IA was detected and we concluded that the therapeutic effect seems to be achieved by this.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
